Pulling the silk off the all-new 2014 Forte sedan today at the Los Angeles International Auto Show, Kia Motors America (KMA) revealed a stunning European design-inspired sedan that makes it clear the Korean auto manufacturer has another winner in its line-up of sought-after cars and CUVs. Sitting on an all-new chassis that is longer, wider and lower than the previous-generation Forte, the all-new third-generation Forte will offer more room, more performance and more premium amenities when it’s expected to go on sale in the first quarter of 2013. The all-new 2014 Forte will be offered in LX and EX variants with a choice of an efficient 1.8-liter engine or a more powerful 2.0-liter engine.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59311-kia-motors-america-unveils-all-new-2014-forte-sedan-at-laias
With its eye-catching design and impressive roster of features, the all-new 2018 Rio sedan and 5-door are the latest additions to the world-class Kia Motors America (KMA) model lineup. Penned at Kia’s European and U.S. design studios in collaboration with Kia’s design base in Namyang, Korea, this subcompact duo will bring an exciting combination of impressive fuel efficiency, innovative technology, advanced safety features4, everyday convenience and fun-to-drive character to value-conscious consumers when they arrive at Kia retailers later this year.
To view the multimedia release go to:
https://www.multivu.com/players/English/8016953-kia-rio-nyias-2017/
Ahead of World Mental Health Day, today sees the publication of the Mental Health Integration Index, a new research initiative commissioned by the Janssen Pharmaceutical Companies of Johnson & Johnson and undertaken by the Economist Intelligence Unit.1 The research explores the challenges of integrating Europeans with mental illness into society and employment, within the European Union’s 28 Member States, plus Norway and Switzerland. Countries have been ranked according to their degree of commitment to support those living with mental illness; the findings demonstrate that while there are many examples of good practice across Europe, the whole region has a long way to go before people with mental illness are adequately supported and truly integrated into their communities.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/72762557-janssen-europe-mental-health-index/
Today, Cision announced the launch of its integrated platform, the Cision Communication Cloud™.
This new offering is the first of its kind in the UK and European communications industry to bring the power of the cloud to earned media and incorporates many of Cision’s award-winning technologies, including Gorkana and PR Newswire products and services, into a single integrated platform, providing an effective way to connect, scale and accurately measure the impact of earned media communications.
Jeremy Thompson, CEO (EMEA & India), Cision/PR Newswire, said: “At Cision, we appreciate that PRs and communicators are busier than ever before, as the power and importance of reputation grows. We have set out to help our users assert control by integrating the essential communications data sets and tools they need at their fingertips in one place.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7961251-cision-communication-cloud/
On World Mental Health Day, Janssen has announced the results of a pan-European research project: ‘Talking About Treatment in Schizophrenia: A Patient and Carer Survey’. The survey of 166 adults living with schizophrenia and 468 carers was conducted by the independent market research agency, Fieldwork International (part of Ipsos MORI), and explored awareness, feelings and preferences regarding treatment.
The survey, conducted across 12 countries in Europe (Austria, Belgium, Denmark, France, Germany, Italy, Netherlands, Russia, Spain, Sweden, Switzerland and the UK), highlighted key factors affecting the peace of mind for carers, such as the impact of the condition on day‑to-day life, potential relapse/hospitalisation and getting support beyond medication. 94% stated they reminded the person they care for to take their medication and for 49% this happens often.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7947151-janssen-survey-carers-adults-schizophrenia/
Quinny and Maxi-Cosi, premier European brands of Dorel Juvenile, a segment of Dorel Industries (TSX: DII.B, DII.A), and the world's largest juvenile products manufacturer in its categories, today announced its most luxurious collection yet, launching globally, from renowned designer, stylist and editor Rachel Zoe. Rachel Zoe x Quinny and Maxi-Cosi merges the brands’ design-forward, high quality and industry leading safety with Zoe’s unparalleled, award-winning fashion sensibility.
“We’re proud to collaborate with a designer of Rachel Zoe’s caliber,” said Dan Pennacchio, General Manager of Premium Brands at Dorel Juvenile USA. “Our partnership with Rachel once again asserts our expertise in providing style-conscious parents with the latest in designer baby gear. Her insights into the worlds of design and motherhood are captured in the collection’s chic, yet classic and functional aesthetic.”
With nearly two decades of experience in design and fashion, Zoe has become a household name embodying sophisticated, timeless style and Hollywood glamour. From designing her eponymous collection, and authoring two New York Times bestselling books, to acting as Editor-in-Chief of digital style destination The Zoe Report, and most recently returning to TV with Lifetime’s “Fashionably Late with Rachel Zoe,” her influence continues to grow. A mom to two young sons, Zoe’s recent, highly-acclaimed maternity wear collection for A Pea in the Pod exemplifies her ever-expanding appeal to women everywhere.
To view the multimedia release go to:
http://www.multivu.com/players/English/7662251-rachel-zoe-quinny-maxi-cosi/
The Eurail Group G.I.E., the organisation dedicated to the marketing and management of the InterRail product range will continue to promote brand awareness during the Dutch Travel Fair between the 12th and 16th January, 2011. The objective is to continue promoting InterRail is for everyone and that, contrary to popular belief, there is no upper age limit.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/interrail/47577/
Raising public awareness of peripheral neuropathic pain (PNP), The Pain Within is a touring exhibition of major European cities which launched today at the 7th congress of the European Federation of IASP Chapters (EFIC) in Hamburg. Top photographer Alex Telfer has worked with patients to capture their experiences in both portraits and visual metaphors for the exhibition, which is sponsored by Astellas Pharma Europe Ltd. It will then tour in other countries in Europe.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/astellastrade/52120/
Urgent action is needed to improve the diagnosis and management of CDI, which is the main cause of hospital-acquired (nosocomial) diarrhoea in industrialised countries.2 In a report launched today, during a meeting hosted by the European Healthcare and Hospital Federation (HOPE), experts from across Europe highlight the current deficiencies in the management of CDI and outline the steps that are needed to address them.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60637-astellas-report-diagnosis-management-CDI
Takeda today announced the launch of a new expert Report on COPD, introduced at a Takeda organised press conference on the occasion of the 2012 European Respiratory Society (ERS) Annual Congress taking place from 1- 5 September in Vienna, Austria.
The Report, entitled ‘The Shifting Paradigm in Chronic Obstructive Pulmonary Disease (COPD) Management,’ was initiated and developed by Takeda Pharmaceuticals International GmbH and is a compilation of opinion articles from a panel of key international respiratory experts, the European Federation of Allergy and Airways Diseases Patients’ Association (EFA) and COPD patients, reflecting updated guidance and research. The new expert Report was developed in response to a recent shift in emphasis in COPD management which now places future risk at equal importance to treatment of current disability. Treatment objectives are now divided into two groups: reducing symptoms and reducing risk.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56582-expert-report-on-copd-launch
Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved IMBRUVICA™ (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor. This new approach to treating blood cancers works by blocking BTK, a protein that helps certain cancer cells live and grow.1 IMBRUVICA is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762540-janssen-ec-approval-imbruvica-mcl-cll/
In June 2015, Shanghai Aerospace Automobile Electromechanical Co., Ltd. (hereinafter referred to as "HT-SAAE") states that HT-SAAE will still be optimistic towards on European PV market’s prospective. During Intersolar Europe 2015 this month, the company will bring its 2015 annual blockbuster product ----“Milky Way” N-type Pert bifacial dual glass module to Munich, and will make a promise to extend the power output guarantee to 30 years for European clients.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7540251-ht-saae-milky-way-glass-pv/
